To hear about similar clinical trials, please enter your email below
Trial Title:
NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer
NCT ID:
NCT02030561
Condition:
Breast Cancer
Gastric Cancer
Conditions: Official terms:
Stomach Neoplasms
Trastuzumab
Conditions: Keywords:
NK cells
trastuzumab
immunotherapy
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Unknown status
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Trastuzumab + NK cells
Arm group label:
Trastuzumab + NK cells
Other name:
Herceptin
Summary:
This study will determine the safety and efficacy of expanded activated autologous NK
cells administered after Trastuzumab in patients with HER2-positive breast or gastric
cancer. It will also provide valuable insights of the role of NK cell infusions in adult
solid tumors.
Detailed description:
Recently, targeted immunotherapies have become part of the therapeutic arsenal in adult
solid tumors, and have shown promising activity in melanomas and prostate cancers.
Trastuzumab is a monoclonal antibody that targets HER2 and is used routinely in
combination with chemotherapy in HER2 over-expressing breast and gastric cancer.
Trastuzumab is known to induce antibody dependent cell cytotoxicity (ADCC), among its
various mechanisms for tumor cell kill. As such, trastuzumab may suitably be combined
with immunotherapy as a strategy to harness the host's immune system against
HER2-positive tumor cells.There is mounting evidence that natural killer (NK) cells have
powerful anti-cancer activity. In patients with leukemia undergoing allogeneic
hematopoietic stem cell transplant, several studies have demonstrated NK-mediated
anti-leukemic activity. Allogeneic NK cell infusions in patients with primary refractory
or multiple-relapsed leukemia have been shown to be well tolerated and void of
graft-versus-host disease (GVHD) effects. In this study, we seek to enhance the antitumor
activity of a commonly used antibody to treat HER2+ breast and gastric cancer,
trastuzumab, administered in combination with infusion of activated and expanded
autologous NK cells.This is a lead-in phase I followed by a phase II study. Up to 9
patients will be enrolled in phase I to test two different doses of NK cells to be
infused into the patient. This will then be followed by a phase II study where 20
patients will be enrolled. Eligible patients will undergo apheresis about 9 days (up to
11 days) prior to cycle 1 therapy to harvest NK cells. The collected NK cells will be
expanded and activated ex vivo. On day 1 of cycle 1, the patient will receive herceptin
and subcutaneous IL2, followed by NK cell infusion on day 2 of cycle 1. This will then be
followed by 5 doses of s/c IL2 three times a week to keep the NK cells activated in vivo.
The patient will then receive three more cycles of herceptin (every 21 days). In patients
who achieve objective tumor response after cycle 2 or cycle 4, a second NK cell infusion
along with s/c IL2 will be administered with cycle 4 or cycle 6 herceptin
respectively.This study will determine the safety and efficacy of this novel therapeutic
strategy in HER2 positive breast and gastric cancer. It will also provide valuable
insights of the role of NK cell infusions in adult solid tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Age 18-65
2. Histologically confirmed diagnosis of HER2-positive breast or gastric cancer
(defined as IHC 3+ or HER2 FISH amplification ratio >2.2)
3. Metastatic disease
4. Presence of measurable tumour by RECIST 1.1 criteria
5. Must have failed at least two lines of trastuzumab-containing systemic therapy
(documented relapse while receiving adjuvant or neoadjuvant trastuzumab for HER2
positive breast cancer is eligible)
6. At least two weeks since receipt of any biological therapy, chemotherapy, and/or
radiation therapy
7. Left ventricular ejection fraction ≥50%
8. Adequate organ function ANC ≥ 1500/µL Platelet count ≥ 100,000/µL Creatinine
clearance ≥60ml/minute Total bilirubin ≤ 1.5 x upper limit normal (ULN) AST ≤ 2 x
upper limit normal ALT ≤ 2 x upper limit normal
9. ECOG performance status of 0-1
10. Life expectancy of at least 60 days
11. Negative serum or urine pregnancy test result within 14 days prior to enrolment for
women who are of childbearing potential
12. Ability to provide informed consent. Otherwise, a legally authorized representative
(LAR) must be present throughout the consent process and is allowed to give consent
on the patient's behalf.
13. Patients with reproductive potential must agree to use an approved contraceptive
method
14. Ability to comply with study procedures
Exclusion Criteria:
1. Treatment within the last 30 days with any investigational drug
2. Concurrent administration of any other tumor therapy, including cytotoxic
chemotherapy, hormonal therapy, and immunotherapy
3. Major surgery within 28 days of study drug administration
4. Active infection that in the opinion of the investigator would compromise the
patient's ability to tolerate therapy
5. Lactating or pregnant.
6. Serious concomitant disorders that would compromise the safety of the patient or
compromise the patient's ability to complete the study, at the discretion of the
investigator; serious cardiac illness or medical conditions including but not
limited to:
- Patients with dyspnea at rest.
- History of documented congestive heart failure
- High risk uncontrolled arrhythmias
- Angina pectoris requiring a medicinal product
- Clinically significant valvular disease
- Evidence of transmural infarction on ECG
- Poorly controlled hypertension
7. Second primary malignancy that is clinically detectable at the time of consideration
for study enrolment
8. Symptomatic brain metastases
9. Receipt of steroids during time period of 3 days prior to expanded NK cell infusion
to 30 days after infusion (i.e. day -3 to day +30).
Gender:
All
Minimum age:
21 Years
Maximum age:
99 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
National University Hospital
Address:
City:
Singapore
Zip:
119228
Country:
Singapore
Status:
Recruiting
Contact:
Last name:
Soo Chin Lee, MBBS
Phone:
+65 6779 5555
Email:
Soo_Chin_Lee@nuhs.edu.sg
Investigator:
Last name:
Dario Campana, MBBS
Email:
Sub-Investigator
Facility:
Name:
National University Hospital
Address:
City:
Singapore
Zip:
119228
Country:
Singapore
Status:
Not yet recruiting
Contact:
Last name:
Soo Chin Lee, MBBS
Phone:
(65) 6779 5555
Email:
Soo_Chin_Lee@nuhs.edu.sg
Investigator:
Last name:
Soo Chin Lee, MBBS
Email:
Principal Investigator
Start date:
January 2014
Completion date:
August 2018
Lead sponsor:
Agency:
National University Hospital, Singapore
Agency class:
Other
Collaborator:
Agency:
National University of Singapore
Agency class:
Other
Source:
National University Hospital, Singapore
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02030561